1 Deal Arena Investors Might Have Missed

Arena Pharmaceuticals  (Nasdaq: ARNA  ) is best known for its weight-loss drug, Belviq, which is slated to hit the U.S. market soon. Its main competition will be VIVUS' (Nasdaq: VVUS  ) Qsymia, and a third biotech -- Orexigen Therapeutics (Nasdaq: OREX  ) -- continues to work toward approval from the Food and Drug Administration for its obesity drug, Contrave.

Arena struck a deal last quarter with South Korean company Ildong to commercialize Belviq in South Korea. Arena is getting $5 million for the deal and will be entitled to more payouts if further milestones are reached.

Recently, Arena expanded its relationship with Ildong to include temanogrel, a drug in the early phases of development that will be aimed at treating arterial thrombosis. In this video, Motley Fool health care analysts Max Macaluso and David Williamson break down this news and discuss why it's too early for investors to start celebrating this deal.

When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 30, 2012, at 5:35 PM, SamFreedom wrote:

    Arena investors are a pretty vocal lot. I wonder why hardly a soul cares to reply much on Motley Fool articles that include ARNA. Could it be they're lame and merelytrying to cash in on the attention?

Add your comment.

DocumentId: 2133109, ~/Articles/ArticleHandler.aspx, 7/24/2014 7:45:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement